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Center
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1 Department of Biology and Microbiology, University of Wisconsin Oshkosh, Oshkosh, Wisconsin, United States of America, 2 Department of Biological Science, Smith
College, Northampton, Massachusetts, United States of America, 3 Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens,
Georgia, United States of America

projects. The following year, he hired entomologist Dr. John W.
McCall to run the repository, because McCall had extensive
experience in maintaining various mosquito species for malaria
studies. Later that year, Dr. Tom Klei joined the filariasis
program as an NIH postdoctoral fellow. At that time, the
repository maintained two filarial species: Litomosoides sigmodontis
(then L. carinii), vectored by the tropical rat mite Ornithonyssus
bacoti; and Acanthocheilonema (then Dipetalonema) viteae, vectored by
the argasid tick Ornithodoros tartakovskyi. Thompson and McCall
became interested in the use of the Brugia system for antifilarial
compound screening when Ash and Riley (University of
California Los Angeles [UCLA]) published the experimental
maintenance of Brugia malayi and Brugia pahangi in Mongolian jirds
(Meriones unguiculatus) [1,2], which are commonly known as gerbils.
McCall obtained B. pahangi–infected dogs and B. malayi–infected
cats from Ash’s laboratory to maintain the parasites for the
repository, and shortly thereafter obtained local Dirofilaria immitis–
infected dogs, bringing the total number of filarial species housed
at the University of Georgia (UGA) facility to five.
In the early days of the FR3, one section of the repository
contract was devoted to contract-related research. The focus of
this component was protocol refinement and development, and
resulted in the birth of many standard experimental filariasis
protocols used today [3–7]. At the time in the late 1960s, the main
laboratory hosts used for filarial species were primates, domestic
dogs, and domestic cats; and filariasis research was limited to
relatively few labs in Japan, Malaysia, the United Kingdom, and
the US. [8–11]. The discovery of gerbil susceptibility to both Brugia
species by Ash and Riley [1,2], and the subsequent development of
the intraperitoneal route of infection by McCall [5], had a
tremendous impact on lymphatic filariasis research worldwide,
and made possible the vast number of studies that have clarified
our understanding of the biology, pathogenesis, and chemotherapy
of filarial infections of humans and other animals. Another major
accomplishment at that time was acquiring a suitable vector

Abstract: Filarial worms cause a variety of tropical
diseases in humans; however, they are difficult to study
because they have complex life cycles that require
arthropod intermediate hosts and mammalian definitive
hosts. Research efforts in industrialized countries are
further complicated by the fact that some filarial
nematodes that cause disease in humans are restricted
in host specificity to humans alone. This potentially makes
the commitment to research difficult, expensive, and
restrictive. Over 40 years ago, the United States National
Institutes of Health–National Institute of Allergy and
Infectious Diseases (NIH-NIAID) established a resource
from which investigators could obtain various filarial
parasite species and life cycle stages without having to
expend the effort and funds necessary to maintain the
entire life cycles in their own laboratories. This centralized
resource (The Filariasis Research Reagent Resource Center,
or FR3) translated into cost savings to both NIH-NIAID and
to principal investigators by freeing up personnel costs on
grants and allowing investigators to divert more funds to
targeted research goals. Many investigators, especially
those new to the field of tropical medicine, are unaware
of the scope of materials and support provided by the
FR3. This review is intended to provide a short history of
the contract, brief descriptions of the fiilarial species and
molecular resources provided, and an estimate of the
impact the resource has had on the research community,
and describes some new additions and potential benefits
the resource center might have for the ever-changing
research interests of investigators.

History of the FR3 and Its Parasite Strains
The United States National Institutes of Health–National
Institute of Allergy and Infectious Diseases (NIH-NIAID)
Filariasis Research Reagent Resource Center (FR3) started in
1969 when Dr. Paul Thompson, professor and later head of the
Department of Parasitology at the University of Georgia College
of Veterinary Medicine (Athens, Georgia), obtained an NIH
contract to establish the Filariasis Chemotherapy and Repository
Research Services. Thompson, the former head of the Antiparasitic Drug Division at Parke Davis Corporation in Ann Arbor,
Michigan, specialized in antimalarial drug testing using Plasmodium berghei as a model. He initially obtained a US Army contract
to perform antimalarial drug screening, and concurrently
procured an NIH grant to study immune mechanisms and
immunizing agents in filariasis and NIH contract funds to
establish a filariasis repository that would function to supply
worms for his filariasis chemotherapy studies and for other
filariasis researchers. In 1969, Drs. Hyong-Sun Ah and John
Hibbard joined Thompson’s filariasis immunology and repository
www.plosntds.org
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Figure 1. Propagation of the Brugia malayi life cycle. (A) Aedes aegypti black-eyed Liverpool strain (CDC Image Bank). (B) Mongolian gerbil
(Meriones unguiculatus) (courtesy of Robert Storey). (C) Brugia malayi adults, 6.36 (courtesy of Dr. Shelly Michalski). The adult male worm is
considerably smaller than the female and is identified by the curved posterior end containing spicules and associated mating structures.
doi:10.1371/journal.pntd.0001261.g001

species that was susceptible for both Brugia species and for D.
immitis. Many different vectors were tested at UGA, including local
mosquitoes; however, acquisition of the black-eyed Liverpool
strain (LVP) of Aedes aegypti developed by MacDonald [12,13] was
a major accomplishment that allowed the FR3 to propagate these
parasites and supply researchers in the US and abroad with ample
worm material to perform their experiments (Figure 1).
After Thompson’s death in 1973, McCall assumed the position
of principal investigator of the Filariasis Repository contract.
Shortly thereafter he partnered with the World Health Organization (WHO) Special Programme for Research and Training in
Tropical Diseases to conduct large-scale antifilarial drug screening
using several gerbil models. These studies were aimed at finding
compounds with adulticidal activity, and, enabled by the largescale production of filarial worms by the FR3, lasted for 25 years.
The model organisms used in compound screening changed over
the years, from gerbils with L. sigmodontis infections in the pleural
cavity, to those with combined L. sigmodontis and B. pahangi
intraperitoneal infections; to intraperitoneal B. pahangi combined
with subcutaneous A. viteae; and finally single intraperitoneal B.
pahangi infections. During that time all five filarial species were
available to filariasis researchers through the Filariasis Repository.
In the later years of the WHO-funded efforts (circa 2000), the
Filariasis Repository ceased production of L. sigmodontis and A.
viteae because they fell out of vogue for drug testing and because
researcher demands had changed predominately to B. pahangi, B.
malayi, and D. immitis. Much of McCall’s efforts in the first 20 years
of heading the FR3 involved protocol development and assisting
principal investigators with experimental design and choosing
appropriate experimental models for their research (Box 1). He
estimates that in his 33-year run as principal investigator of the
FR3, approximately 20–25 different academic research labs used
www.plosntds.org

Box 1. Testimonials
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‘‘FR3 has been and continues to be the lifeline for
filariasis research in our laboratory. Friendly staff and
international experts make this a unique support service
for filariasis community. My collaborators in India and
Malaysia also significantly benefit out of the excellent
service provided by the FR3.’’ Ramaswamy Kalyanasundaram, University of Illinois College of Medicine at
Rockford
‘‘Extremely vital service; without such service our studies
would have been impossible, and thus the development
of novel molecular tools for post-genomic research
would have been hindered.’’ Sara Lustigman, New York
Blood Center
‘‘Without FR3, we would not be able to do research on
filariasis. It is essential that a central resource of high
quality, reliable, and consistent material be available. The
cost of duplicating this resource all the labs which use it
would be staggering.’’ Timothy Geary, McGill University
‘‘The life cycle is complicated and it would not be
feasible to maintain the vectors and the rodent models
in Canada. From what I remember of FR3, there is a real
‘art’ to maintaining these life cycles, an expertise that
might take a lifetime to obtain. FR3 is the best.’’
Bernadette Ardelli, Brandon University
‘‘The capacity of the FR3 to provide unique parasite
resources is CRITICAL to my work. My NIH-funded and
other research would not be possible without the support
of the FR3.’’ Michael Kron, Medical College of Wisconsin
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Figure 2. The geographic locations of recipient laboratories for FR3 parasite reagents. Country flags obtained from http://www.publicdomain-image.com and http://www.clker.com.
doi:10.1371/journal.pntd.0001261.g002

is synonymous with McCall and his efficient team of research
technicians who tirelessly trained filariasis researchers in experimental maintenance of filarial worms, and facilitated hundreds of
shipments of filariasis materials to academic researchers worldwide. That team included Mrs. Jung Ja Jun, who worked at the
FR3 for 33 years; and Drs. Mike Dzimianski and Prasit
Supakorndej, who remain at the FR3 with 28 and 25 years of

the parasite service at any one time, for a total of hundreds
throughout 14 countries (Figure 2).
The filarial service changed names a number of times over the
years, but eventually became known as ‘‘the FR3’’ (Filariasis
Research Reagent Resource Center), and the current contract is
funded under the NIH NIAID Animal Models of Infectious
Disease program (Box 2). For many filariasis investigators, the FR3
www.plosntds.org
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(Department of Infectious Diseases, UGA), who guided the
transition of the contract, and in 2011 was assumed by Dr.
Andrew Moorhead (Department of Infectious Diseases, UGA).
In 2003, filarial resource services were greatly expanded when
the success of the WHO-funded Filarial Genome Project (FGP)
spurred the creation of a Molecular Resources Division of the
FR3. This division is based at Smith College in Northampton,
Massachusetts, and provides filariasis researchers with molecular
and serological reagents, and is responsible for development of
new molecular reagents and tools. It is headed by Dr. Steven
Williams. The most recent change to the infrastructure of the FR3
came with the addition of a new FR3 Communication Division
based at the University of Wisconsin Oshkosh, headed by Dr.
Shelly Michalski. The responsibilities of this division include
facilitating communication between the filariasis research community and the FR3 through annual user surveys and e-mail
communications, advertising of the FR3 and the FR3 minicourse
at scientific meetings, contributing to the FR3 minicourse
curriculum, and maintaining the FR3 website and developing it
into a multifaceted resource for filariasis research and education.
The FR3 has a Scientific Advisory Committee (SAC) that
annually reviews its performance and provides advice to the
director and to NIAID as to the needs of the scientific community
for research agents; and on prioritization of molecular, biological,
and/or genomic acquisitions as they become available. Since
2003, the three scientists who have comprised the SAC are Dr.
Sara Lustigman, Member and Head, Laboratory of Molecular
Parasitology, New York Blood Center; Dr. Eric Ottesen, Director
Lymphatic Filariasis Support Center at The Task Force for Global
Health; and Dr. Thomas Unnasch, Professor in the Department of
Global Health, University of South Florida. These individuals are
highly accomplished and respected members of the filariasis
scientific community and together have expertise in molecular
biology, immunology, genomics, proteomics, transgenics, vector
biology/parasitology, pathogenesis of filariasis, and filariasis
elimination programs.

Box 2. Key Learning Points
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For over 40 years, NIH-NIAID has supported a filariasis
resource center to provide research material, free of
charge, to hundreds of principal investigators in
industrialized and developing countries. Easy access to
these materials has resulted in hundreds of peerreviewed manuscripts, meeting abstracts, book chapters,
and graduate theses. Investigators in academia, not-forprofit organizations, industry, and government worldwide may receive FR3 services.
The FR3 Parasite Resources Division offers life cycle
stages of three filarial species (and their vectors): B.
malayi, B. pahangi, and D. immitis. The Brugia strains,
correctly denoted as ‘‘FR3 strains’’, were originally
collected in Kuala Lumpur in the late 1950 s/early
1960 s. They are the same strains carried by TRS
Laboratories.
The FR3 Molecular Resources Division offers filarial
(Brugia spp., Onchocerca spp., W. bancrofti) cDNA and
genomic clones, as well as anti–B. malayi Wolbachia
surface protein wBm0432 monoclonal antibody, through
BEI resources. They also offer filarial RNA and DNA
preparations, the version 2 B. malayi microarray, and
serologic reagents as well as endemic serum samples,
through Smith College.
FR3 services include personalized support for experimental questions (just call us!), an upgraded website
with precise information about currently available FR3
resources and helpful links to protocols, parasite-related
media, and upcoming events; a free, annual, week-long
workshop offering lecture and laboratory courses taught
by experts in filariasis research; and an informational
booth that is displayed at the annual American Society
for Tropical Medicine and Hygiene meeting where
researchers can meet and greet FR3 personnel and users.
The FR3 is committed to addressing the changing needs
of its users, and assesses those needs by means of an
annual electronic survey. This practice has allowed us to
enrich and streamline our services to best meet the
demands of the research community. Continued cooperation by the filariasis community in these surveys is the
key to maintaining up-to-date services.
Filariasis Research Reagent Resource Center website:
http://www.filariasiscenter.org/
NIH NIAID Resources for Researchers website: Filariasis
Research Reagent Resource Center: http://www.niaid.
nih.gov/labsandresources/resources/dmid/fila/Pages/de
fault.aspx
NIH NIAID Resources for Researchers website: Animal
Models of Infectious Disease: http://www.niaid.nih.gov/
LabsAndResources/resources/dmid/animalModels/Pag
es/default.aspx

Filarial and Vector Species Provided
At its inception, the FR3 maintained five filarial species, their
vertebrate hosts (dogs for D. immitis and B. pahangi, cats for B.
malayi, cotton rats and Mongolian gerbils for L. sigmondontis, and
gerbils for A. viteae, B. malayi, and B. pahangi), and their vectors (the
aforementioned tick and mite species for A. viteae and L. sigmodontis,
respectively), and A. aegypti LVP strain (for D. immitis, B. malayi, and
B. pahangi). The previous contract, spanning 2003–2010, focused
mainly on the production of D. immitis, B. pahangi, and B. malayi.
During this time period, the FR3 responded to over 2,000 requests
from almost 80 researchers for parasite materials. The number of
requests for parasites has remained relatively stable over the period
of the contract; however, changes in user trends have been
apparent, primed largely by advances in molecular techniques that
have enabled more studies on the human pathogen B. malayi. In
general, requests for B. pahangi and D. immitis have generally
decreased, while those for B. malayi (particularly for microfilaremic
blood) have increased. Keeping current with the changing needs of
filariasis researchers has proven challenging; however, the
circulation of an annual user survey has helped the FR3 adjust
to meet user requests (e.g., increasing the number of B. malayi–
infected cats and augmenting mosquito production to meet an
overall anticipated increase in requests for the third-stage larvae of
D. immitis, B. malayi, and B. pahangi). Most recently, requests from
users conducting comparative work on the filarial Wolbachia
endosymbiont has resulted in additional funding for the 2011–

experience, respectively. In 1980, when avermectins were being
tested as potential anthelmintics, McCall embarked on a private
venture (TRS Labs, Athens, GA) to conduct large-scale anti-filarial
drug screening that was not possible at UGA due to space
constraints. McCall retired from the FR3 in 2006, and oversees
,30 projects per year mainly on chemotherapy of canine
heartworm, fleas, ticks, and gastrointestinal parasites at TRS.
TRS also supplies all five species of filarial worms and their vectors
at cost for filariasis researchers. After McCall’s retirement, the role
of project director of the FR3 was taken on by Dr. Ray Kaplan
www.plosntds.org
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Figure 3. The geographic locations of recipient laboratories for FR3 molecular reagents. Country flags obtained from http://www.publicdomain-image.com and http://www.clker.com.
doi:10.1371/journal.pntd.0001261.g003
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propagation, isolation and observation of different filarial life cycle
stages from vertebrate and invertebrate hosts, filarial nucleic acid
purification and characterization, DNA and quantitiative RTPCR, and host animal biology and handling. The minicourse is
held at the University of Georgia (Athens, Georgia), and is free of
charge; FR3 personnel and filariasis researchers teach lecture and
laboratory sessions. To date, more than 50 people have
participated in the minicourse, and anonymous satisfaction surveys
administered on the last day of the course overwhelmingly indicate
that the course met or surpassed the expectations of participants
(Box 3), who enjoy the small class size, broad experience, and
interaction with filariasis experts. From 2009 to 2011, the
breakdown of participant type was 12% government employee,
18% faculty, 3% technician, 26% graduate students, 12%
postdoctoral fellows, 6% undergraduates, 3% veterinary students,
17% industry, and 3% medical doctors. When recalling the vast
number of researchers that he helped individually over the early
years of the FR3, John McCall remarked that ‘‘the FR3
minicourse would have been nice then’’.
The FR3 website (http://www.filariasiscenter.org/) offers
investigators the capability of ordering resources online and
accessing parasite-related and molecular protocols to facilitate
their research programs. Features of the website include detailed
lists of parasite and molecular reagents, online parasite and
molecular resources ordering, a parasite resources inventory list
that is updated monthly, information about the annual minicourse,
pictures and videos submitted by the filariasis research community,
helpful tips for filariasis researchers, an events calendar that
displays upcoming scientific meetings, a live RSS feed that displays
recent filariasis-related articles, links to filariasis/nematode/
Wolbachia–related websites, and a filarial genomics and bioinformatics section that includes B. malayi genome data and microarray
annotation, as well as comparative genomic information to
Caenorhabditis elegans. The digital content of the website is
continually being expanded, so that it may serve as a centralized
resource for the filariasis research community.

2012 contract year to re-establish the A. viteae life cycle at UW
Oshkosh.

Molecular Reagents
The molecular reagents collection began in 1994 when the
WHO initiated the FGP and established the laboratory of Steven
Williams as the resource center for cDNA and genomic libraries
and clones as well as other genomic reagents. With assistance from
the laboratories of Drs. Mark Blaxter (University of Edinburgh),
Barton Slatko (New England Biolabs), Alan Scott (Johns Hopkins
University), and Sara Lustigman (New York Blood Center), the
FGP Resource Center initially distributed cDNA libraries and
cDNA clones. These cDNA libraries were used in the first stage of
the B. malayi genome project for EST sequencing and gene
identification [14]. Every cDNA clone that was sequenced was
stored, and over 37,000 cDNA clones are now individually
available through the FR3. This set of cDNA clones was recently
duplicated and sent to the Biodefense and Emerging Infections
Research Resources Repository (BEI Resources, http://www.
beiresources.org/) for distribution to the scientific community
under a new arrangement with NIAID.
In total, 25 cDNA libraries are available through FR3 and
include libraries for various stages of B. malayi, Wuchereria bancrofti,
Onchocerca volvulus, and Onchocerca ochengi. Genomic libraries in
bacteriophage lambda are available for B. malayi and O. volvulus, as
well as a genomic BAC library that was used to map and sequence
the Wolbachia genome of B. malayi [15,16]. Using both EST and
genome sequence data from the B. malayi genome project [17,18]
and data available from Wolbachia, W. bancrofti, and O. volvulus, a
total of 18,153 oligonucleotides were synthesized for spotting on B.
malayi microarrays. These version 2 microarrays were developed
by a consortium of researchers and are currently available by
request from the FR3.
The FR3 also has a variety of protein molecular reagents,
including a serum bank with sera from infected and uninfected
patients, the Bm14 antigen for serologic monitoring, and the
positive control for the Binax Filariasis NOW test. The serum
bank includes two separate collections: 1) the O. volvulus serum
bank with 340 serum samples from Ecuador, Togo, Nigeria, and
Cameroon, and 2) the filariasis serum bank with 363 sera from
Africa, Asia, and South America. Newly available for 2011 are the
monoclonal antibody mAb Bmwsp, raised against B. malayi
Wolbachia surface protein wBm0432 [19], that is available through
BEI Resources (http://www.beiresources.org/), as well as userready filarial RNA and DNA preparations (including whole
genome-amplified Wuchereria bancrofti DNA) that are available
through Smith College. The Molecular Division of the FR3 has
proven to be a valuable resource for the filariasis research
community and has to date provided researchers in 34 countries
with filarial molecular reagents (Figure 3).

Box 3. Comments from FR3 Minicourse
Participants, as Part of the Anonymous Course
Evaluation

N
N
N
N

Other Services: Education and Training, and the
FR3 Website

N

In 2006, the FR3 began offering a hands-on annual minicourse
to introduce students, postdoctoral fellows, principal investigators,
university professors, and industry representatives to a variety of
organismal and molecular techniques commonly used in filariasis
research. Lectures are given daily and include topics related to
vector and nematode biology, experimental models of filarial
disease, FR3 molecular and parasite resources, molecular data
analysis and reporting, bioinformatics, pathogenesis, and control
of filarial diseases. Daily hands-on lab exercises involve vector
www.plosntds.org
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‘‘A comprehensive introduction to the world of filarial
parasite research. Instructive hands-on training and
exciting demonstrations!’’
‘‘It was a great experience to get to know some other
members of the filarial research community.’’
‘‘If you’d like to learn a lot about filariasis, worms, or
parasitology you have to join this course!’’
‘‘The FR3 workshop is not only very valuable for learning
various aspects of filarial research, but is also very
engaging, meeting all my expectations and more!’’
‘‘This was a great all-Inclusive program that taught not
only whole organism but also vector interactions and
molecular biology. Anyone wanting to take a crash
course in filarial worm biology and actually come out
feeling like they can design their own experiments
should take this minicoursel’’
‘‘The FR3 workshop is not only very valuable for learning
various aspects of filarial research, but is also very
engaging, meeting all my expectations and more!’’

November 2011 | Volume 5 | Issue 11 | e1261

accurate number of publications in experimental schistosomiasis
that have been made possible through the use of this resource over
the 40-plus years of its existence.’’ We echo these sentiments in
regards to the FR3, because it would be impossible to count not
only the published manuscripts, theses, and abstracts made

Impact of the Resource on Research Community
A previous publication on the NIAID Schistosomiasis Resource
Center summed up its impact on the schistosomiasis research
community [20] by stating ‘‘It would be impossible to give an
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possible by our services, but also the number of researchers that
have obtained help with experimental design, protocol implementation, and hands-on knowledge of working with filarial nematodes
and their hosts. A comprehensive search of standard literature
databases reveals that over the last 3 years, approximately 68% of
experimental filariasis papers are from laboratories that use FR3
services; and that over the last 4 years, approximately 50% of all
filariasis presentations at the American Society for Tropical
Medicine and Hygiene annual meeting acknowledged the FR3.
Box 4 highlights the diversity of original studies made possible by
the FR3; a complete list of peer-reviewed manuscripts that have
cited the FR3 is available as Text S1, and is also on the FR3
website (http://www.filariasiscenter.org/).

Both were derived from infections that Dr. John Schacher had
kept in dogs and cats when he was at American University in
Beirut, Lebanon, before himself relocating to UCLA in the late
1960s. Schacher originally obtained these infections from
researchers in Kuala Lumpur (Larry Ash, personal communication). The D. immitis strain currently propagated at the FR3 was
obtained from TRS labs and is denoted as the Missouri 2005
strain. When publishing work that involves the use of FR3
resources, please acknowledge the NIH/NIAID Filariasis Research Reagent Resource Center (http://www.filariasiscenter.org/)
for relevant materials.

Supporting Information
Text S1 Papers made possible by FR3.

Strain Names, and Acknowledging the FR3

(DOC)

The FR3 provides parasite and molecular materials for only the
charge of shipping to academic researchers, teaching institutions,
and for-profit industrial researchers. New users must submit a
registration form and completed material transfer agreements
prior to receiving shipments; these documents are available on the
FR3 website (http://www.filariasiscenter.org/). The B. malayi and
B. pahangi strains that have been propagated at the FR3 since 1970
have been referred to by several different names (e.g., TRS,
McCall, FR3); they are correctly referenced as the ‘‘FR3’’ strains.
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